- Home
- AWP vs ESPR Comparison
AWP vs ESPR Comparison
Compare AWP & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWP
- ESPR
- Stock Information
- Founded
- AWP 2007
- ESPR 2008
- Country
- AWP United States
- ESPR United States
- Employees
- AWP N/A
- ESPR N/A
- Industry
- AWP Trusts Except Educational Religious and Charitable
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- AWP Finance
- ESPR Health Care
- Exchange
- AWP Nasdaq
- ESPR Nasdaq
- Market Cap
- AWP 331.0M
- ESPR 305.0M
- IPO Year
- AWP N/A
- ESPR 2013
- Fundamental
- Price
- AWP $3.91
- ESPR $0.80
- Analyst Decision
- AWP
- ESPR Buy
- Analyst Count
- AWP 0
- ESPR 7
- Target Price
- AWP N/A
- ESPR $5.93
- AVG Volume (30 Days)
- AWP 331.5K
- ESPR 5.5M
- Earning Date
- AWP 01-01-0001
- ESPR 05-06-2025
- Dividend Yield
- AWP 12.48%
- ESPR N/A
- EPS Growth
- AWP N/A
- ESPR N/A
- EPS
- AWP N/A
- ESPR N/A
- Revenue
- AWP N/A
- ESPR $259,574,000.00
- Revenue This Year
- AWP N/A
- ESPR $5.70
- Revenue Next Year
- AWP N/A
- ESPR N/A
- P/E Ratio
- AWP N/A
- ESPR N/A
- Revenue Growth
- AWP N/A
- ESPR 12.99
- 52 Week Low
- AWP $3.06
- ESPR $0.82
- 52 Week High
- AWP $4.20
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- AWP 57.18
- ESPR 32.43
- Support Level
- AWP $3.90
- ESPR $0.93
- Resistance Level
- AWP $3.95
- ESPR $1.11
- Average True Range (ATR)
- AWP 0.06
- ESPR 0.11
- MACD
- AWP 0.02
- ESPR 0.01
- Stochastic Oscillator
- AWP 70.83
- ESPR 17.93
About AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.